Earnings Call Summary | Dyadic(DYAI.US) Q4 2023 Earnings Conference
Earnings Call Summary | Dyadic(DYAI.US) Q4 2023 Earnings Conference
The following is a summary of the Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript:
以下是Dyadic International, Inc.（DYAI）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Dyadic reported a slight decrease in research and development revenue and license revenue for FY 2023, totaling about $2.9 million, down from $2.93 million in FY 2022.
Cost of research and development revenue was reduced to approximately $2 million, compared to $2.1 million in the previous year.
The company raised $6 million in convertible promissory notes and has cash and investment-grade securities of $7.3 million, further supplemented with newly raised funds and from the sale of their equity interest in Alphazyme.
The net loss for 2023 was approximately $6.8 million, or $0.24 per share, which is an improvement from the $9.7 million or $0.34 per share in 2022.
Other cash inflows were reported from previous equity agreements with Alphazyme and BDI.
Dyadic報告稱，2023財年的研發收入和許可收入略有下降，總額約爲290萬美元，低於2022財年的293萬美元。
研發收入的成本從上一年的210萬美元降至約200萬美元。
該公司籌集了600萬澳元的可轉換期票，並擁有730萬澳元的現金和投資級證券，此外還有新籌集的資金和出售Alphazyme的股權。
2023年的淨虧損約爲680萬美元，合每股虧損0.24美元，較2022年的970萬美元或每股虧損0.34美元有所改善。
其他現金流入來自先前與Alphazyme和BDI的股權協議。
Business Progress:
業務進展：
Dyadic has reported success in their Phase I human trial of their C1 protein, demonstrating safety and efficacy.
Collaborations have been established with entities like Rabian BV and the Israel Institute for Biological Research. Similarly, agreements have been made with top 5 pharmaceutical companies for developing antigens for various diseases.
Partnerships and product opportunities have been started in the non-pharmaceutical sector, including alternative proteins and bio-industrial sectors.
The leadership team expanded the responsibilities for the Chief Business Officer, Joe Hales, making him Chief Operating Officer, and appointed Patrick Lucy as Chairman.
Dyadic's C1 protein has completed its trial phase positioning the company for commercialization.
Dyadic is adjusting its business strategies to capitalize on present opportunities and those expected in the near future, including the expansion of the usage of Dapibus platform in food production, among other applications.
Dyadic報告說，其C1蛋白的I期人體試驗取得了成功，證明了安全性和有效性。
已經與Rabian BV和以色列生物研究所等實體建立了合作關係。同樣，已經與排名前五的製藥公司達成協議，爲各種疾病開發抗原。
非製藥領域，包括替代蛋白和生物工業領域，已經開始了合作伙伴關係和產品機會。
領導團隊擴大了首席商務官喬·海爾斯的職責，任命他爲首席運營官，並任命帕特里克·露西爲董事長。
Dyadic的C1蛋白已經完成了其試驗階段，爲公司做好了商業化準備。
Dyadic正在調整其業務戰略，以利用當前的機會和不久的將來預期的機會，包括擴大Dapibus平台在食品生產中的使用範圍以及其他應用。
More details: Dyadic IR
更多詳情： 二進制紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。